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Abstract  
Health-related quality of life (HRQoL) scores assess symptom burden in pulmonary arterial 
hypertension (PAH) but data regarding their role in prognostication and risk stratification are limited. 
We assessed these relationships using the emPHasis-10 HRQoL measure. 
1745 patients with idiopathic or connective tissue disease-associated PAH who had completed 
emPHasis-10 questionnaires between 2014-17 at 6 UK referral centres were identified. Correlations 
with exercise capacity and WHO functional class (FC) were assessed, and exploratory risk 
stratification thresholds were tested. 
Moderate correlations were seen between emPHasis-10 scores and 6-minute walk distance (r=-
0.546), incremental shuttle walking distance (r=-0.504) and WHO FC (r=0.497; p all <0.0001). 
Distribution of emPHasis-10 differed significantly between each WHO FC (p all <0.0001). At 
multivariate analysis, emPHasis-10, but not WHO FC, was an independent predictor of mortality. In a 
risk stratification approach, scores of 0-16, 17-33 and 34-50 identified incident patients with one-
year mortality of 5%, 10% and 23%, respectively. Survival of patients in WHO FC III could be further 
stratified using an emPHasis-10 score ≥34 (p<0.01). At follow-up, patients with improved emPHasis-
10 had improved exercise capacity (p<0.0001), and patients who transitioned risk groups 
demonstrated similar survival to patients originally in those risk groups. 
The emPHasis-10 score is an independent prognostic marker in patients with idiopathic or 
connective tissue disease-associated PAH. It has utility in risk stratification in addition to currently 





Pulmonary arterial hypertension (PAH) is a rare condition, characterised by increased pulmonary 
vascular resistance and progressive right ventricular failure leading to premature death (1). 
Exertional breathlessness and limitation in physical activity are typically the earliest reported 
symptoms and may be caused by a number of mechanisms (2, 3). Exercise limitation may be 
objectively assessed by exercise testing, but limitations of day-to-day physical activity are typically 
assessed by healthcare professionals using the World Health Organisation (WHO) functional class.  
The importance of assessing patient reported outcome measures (PROMs) in patients with 
pulmonary hypertension (PH) is now recognised (4, 5) and three PH-specific tools for assessing 
health-related quality of life (HRQoL) have been developed (6-8). One of these tools, emPHasis-10, is 
comprised of 10 fields (resulting in a score out of 50, where a higher score represents a higher 
symptom burden) which can be quickly completed by patients and is free to use and so is well suited 
to routine clinical use (7). The emPHasis-10 score was found to correlate strongly with measures of 
HRQoL, breathlessness and psychological morbidity and has high test-retest and internal consistency 
(7). In addition, the emPHasis-10 questionnaire has been translated into a number of other 
languages (9, 10). A previous single-centre study of emPHasis-10 in patients with PAH 
(predominantly congenital heart disease-associated) and chronic thrombo-embolic PH demonstrated 
prognostic significance and a correlation with WHO functional class (FC) (11). Although risk 
stratification has an established central role in the management of patients with PAH, PROMs are 
not incorporated in current risk assessment tools (12-14). 
Routine HRQoL assessment using a PH-specific tool has been a mandatory field in the UK National 
Audit of Pulmonary Hypertension since 2014 (15). We performed a multi-centre study on a large 
cohort of patients with idiopathic and connective tissue disease (CTD)-associated PAH, to further 
assess the relationship between emPHasis-10 score and mortality, identify correlations with clinical 
parameters, including exercise capacity, and determine whether a threshold approach for risk 





Local databases for 6 out of the 7 UK pulmonary hypertension referral centres, which together 
manage 94% of adult patients with a diagnosis of PAH, were interrogated (15). Patients with PAH 
were diagnosed as per contemporaneous international guidelines (mean pulmonary arterial 
pressure ≥25mmHg and pulmonary arterial wedge pressure ≤15mmHg in the absence of 
thromboembolic disease or conditions associated with other forms of pulmonary hypertension) (16). 
Anonymised demographic, haemodynamic, spirometric, exercise, emPHasis-10 and mortality data 
were retrieved for all patients with a diagnosis of idiopathic, drug-associated or heritable PAH 
(hereafter grouped as IPAH) or PAH related to CTD (CTD-PAH) with at least one recorded emPHasis-
10 score between January 1
st
 2014 and 31
st
 May 2018. Incident patients were required to have an 
emPHasis-10 score at the point of diagnosis, which was possible if diagnosed from 2014 onwards 
since its clinical use was introduced in the UK during that year. For prevalent patients (i.e. those 
diagnosed prior to 2014 or for whom no emPHasis-10 score was available at the time of diagnosis) 
the first available emPHasis-10 score was used. In either group, the first emPHasis-10 score was 
described as the baseline measurement. All patients were under regular clinical follow-up and the 
outcome measured was death or transplant by 31
st
 May 2019. Follow-up data were retrieved for the 
first visit between 3 and 12 months after baseline emPHasis-10 score.  
 
Statistical Analysis 
Statistical analysis was performed using SPSS v26 (IBM, Chicago) and GraphPad Prism v8. Continuous 
data were displayed as either mean ± standard deviation, or median (first quartile, third quartile) for 
non-parametric data. Demographics were compared using paired and unpaired T-test for parametric 
data, and Wilcoxon signed-rank and Mann-Whitney U-tests for non-parametric data. Frequencies 
were compared using Χ2. For Cox regression modelling, parameters of known prognostic significance 
in PAH were utilised: age, gender, presence of CTD (rather than IPAH), mean right atrial pressure, 
cardiac index and walking distance. Collinearity was assessed by measuring the variance inflation 
factor and tolerance between variables. EmPHasis-10 score was entered as a continuous variable in 
the multivariable model. Multivariate Cox regression analysis was performed in a forward direction 
on all parameters with a p value <0.2 at univariate analysis. Data were scaled to the mean and 
hazard ratios were based on the z-score. Two types of walking test were used (the 6-minute walking 
test (6MWT) and incremental shuttle walking test (ISWT)) and so for multivariate modelling, 
distances were converted to a z-score and combined as a single variable. For all statistical tests other 
than multivariate analysis, a p value of <0.05 was considered significant. Kaplan-Meier survival 
curves were compared using log rank Χ2, and were truncated at 4 years, based on the census date. 
Correlations were assessed using either Pearson or Spearman rank, as appropriate. Risk models 
were compared using the c-statistic identified from receiver operating characteristic (ROC) curve 
analysis. The minimal detectable change (MDC) for emPHasis-10 score was calculated using the 
formula: MDC = 1.96 x √2 x standard error of measurement.(17) 
Ethical approval was granted (IRAS 254446). 
 
Results 
A total of 1745 patients with IPAH (n=994) or CTD-PAH (n=751) who had at least one recorded 
emPHasis-10 score were identified. There was a female predominance (73%), and 35% of patients 
were incident and treatment-naïve at the time of baseline emPHasis-10 score. The median 
emPHasis-10 score was higher in patients with CTD-PAH (median 30 (19, 38)) than patients with 
IPAH (28 (17, 37)); p=0.001. Baseline demographics are displayed in table 1. 
 
Correlation with clinical parameters 
Moderate correlations (p all <0.0001) were seen between baseline emPHasis-10 score and WHO FC 
(r=0.50), 6MWT distance (6MWD; r=-0.55) and ISWT distance (ISWD; r=-0.50), table 2. In incident 
patients with right heart catheter data available (n=591), there were weak correlations with mean 
right atrial pressure (mRAP; r=0.21), cardiac index (r=-0.21) and pulmonary vascular resistance (PVR; 
r=0.17); p all <0.0001. Correlations were similar in subgroups of IPAH and CTD-PAH, apart from PVR 
where correlation was significant in CTD-PAH (r=0.21; p<0.0005) but not in IPAH (r=0.11; p=0.8). 
Correlations between WHO FC and walk distance and haemodynamics are also shown in table 2. 
Distribution of emPHasis-10 score by WHO FC at baseline is shown in figure 1; median emPHasis-10 
scores were 3, 19, 31 and 40 in WHO FC I, II, III and IV, respectively, with highly significant 




During the course of the study 674 (39%) patients died, of which 240 (14%) died within one-year of 
baseline emPHasis-10 score; one-year mortality in incident and prevalent patients was 16% and 12%, 
respectively. An exploratory three-level score was developed based on a tertile group approach: 
scores of 0-16 were defined as low-risk, 17-33 as intermediate-risk, and 34-50 as high-risk. Using 
these thresholds, 22% of all patients were defined as low-risk, 41% as intermediate-risk and 37% as 
high-risk of one-year mortality. Survival curves for these risk groups are shown for incident patients 
in figure 2a, prevalent patients in figure 2b, and for all patients in figure 2c. In incident patients, one-
year mortality for the low, intermediate and high-risk groups was 5%, 10% and 23%, respectively, 
and in prevalent patients one-year mortality for the low, intermediate high-risk groups was 4%, 13% 
and 20%, respectively. In all patients, one-year mortality for the low, intermediate and high-risk 
groups was 4%, 12% and 21%, respectively. In all patients with IPAH, one-year mortality in low, 
intermediate and high-risk groups was 4%, 9% and 18%, whereas in CTD-PAH, one-year mortality 
was 6%, 15% and 25%, respectively. Incident patients in functional class III who were in 
low/intermediate emPHasis-10 risk groups (emPHasis-10 score 0-33) had superior survival than 
those in the high-risk group (emPHasis-10 score 34-50) with 1 and 3-year survival of 90% and 67% vs 
81% and 56%; p<0.01; figure 3). Very similar observations were made in functional class III patients 
at their first follow-up visit. 
 
Survival Analysis  
Three multivariate analysis models were developed in the incident population (table 3). Model 1 
utilised accepted prognostic parameters: age, gender, CTD-PAH rather than IPAH, WHO FC, mRAP 
and cardiac index. EmPHasis-10 and exercise capacity were sequentially added into models 2 and 3. 
Unlike WHO FC, emPHasis-10 score was an independent predictor of outcome in models 2 (scaled 
HR 1.565; p<0.0001) and 3 (scaled HR 1.226; p<0.05). There was no significant collinearity between 
parameters used in the model. 
 
Magnitude of change 
The MDC for emPHasis-10 score was calculated to be 9. Follow-up emPHasis-10 data were available 
for 1068 patients (61%). EmPHasis-10 score changed by at least 9 points in 33% of patients (IPAH 
32%, CTD-PAH 34%) between baseline and follow-up. Thirty-seven percent of patients moved risk 
groups, of which 19% improved at least one risk group. In patients who moved from high-risk to 
intermediate or low-risk, the median change in emPHasis-10 score was -12 (-6, -19) points, and in 
patients who deteriorated to high-risk the median change was +13 points (+8, +17). Patients who 
either improved to low or intermediate-risk, or deteriorated to high-risk demonstrated similar long-
term survival to patients originally in those risk groups (figure 2d).  
At paired testing in patients with a follow-up emPHasis-10 score, those who improved emPHasis-10 
score by ≥ the MDC of 9 points had significantly improved walk distances at follow-up; ISWD 
increased by 30m (0, 90; p<0.0001, figure 4a) while 6MWD increased by a median distance of 32m (-
4, +113; p<0.005, figure 4b). A significant fall in ISWD of -20m (-60, 0; p<0.0001, figure 4a) and no 
significant change in 6MWD (0m (-29, +57), figure 4b) was observed in patients whose emPHasis-10 
score deteriorated by at least 9 points. In the remaining patients in whom there was a change of <9 
points there was no significant change in either ISWD (0m (-30, +20)) or 6MWD (0m, (-11, +53)).  The 
relationship between change in emPHasis-10 and change in walk distance differed depending on 
whether patients were incident or prevalent at the time of their baseline walk (relationship being 
stronger in incident patients) and whether they performed the ISWT or 6MWT (relationship being 
stronger in patients who performed the ISWT). In patients whose emPHasis-10 score deteriorated by 
≥9 points, ISWD fell significantly in both incident and prevalent populations. In patients whose 
emPHasis-10 score improved ≥9 points ISWD increased significantly in incident, but not prevalent, 
patients (figure 4c and 4e). In patients in whom a 6MWT was performed, an improvement was 
observed in incident patients whose emPHasis-10 score either improved or deteriorated by ≥9 
points (figure 4d), while no significant change was seen in prevalent patients (4f). 
 
Discussion 
To our knowledge, this is the largest study to assess the role of quality of life scores in patients with 
PAH, and in this multi-centre study we report on data from centres treating the vast majority of the 
adult PAH population in the UK. We have demonstrated that the emPHasis-10 score is an 
independent predictor of outcomes when adjusting for haemodynamics and WHO FC and also has 
utility in risk stratification, including within patients in WHO FC III.  We have also observed moderate 
correlations with WHO FC and exercise capacity and weaker correlations with pulmonary 
haemodynamics. Furthermore, we have also demonstrated that improvement in emPHasis-10 score, 
as opposed to a static or worsening score, is associated with improvements in exercise capacity. 
Generic (Short Form Health Survey (SF-36)), heart failure-specific (Minnesota Living with Heart 
Failure questionnaire), and PAH-specific (emPHasis-10 and Cambridge Pulmonary Hypertension 
Outcome Review (CAMPHOR)) PROMs have previously been identified as having prognostic 
importance in PAH (11, 18-20). Correlations between CAMPHOR and SF-36 and 6-minute walking 
test distance have also been demonstrated (19, 21, 22). The widespread clinical use of the 
CAMPHOR score may, however, be limited by its length (65 fields over 3 domains: symptoms, 
functioning and quality of life) and lack of open access (23). A third PH-specific PROM, the 
Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) tool, which consists of 22 
fields over 2 domains (symptoms and impacts) has also been developed (8). Although PAH-SYMPACT 
is responsive to change, its relationship to haemodynamics and survival is not known (24).  
A previous single-centre study involving 687 patients (314 PAH associated with congenital heart 
disease, 109 IPAH, 111 CTD-PAH and 131 chronic thromboembolic PH) assessed the relationship 
between emPHasis-10 and survival (11). In that study, Cox regression analysis demonstrated 
emPHasis-10 to be predictive of survival, independent of WHO FC, in PAH associated with congenital 
heart disease, but not in IPAH and CTD-PAH. In our study, which included much larger numbers of 
patients with IPAH and CTD-PAH, emPHasis-10 was an independent prognostic marker in IPAH and 
CTD-PAH, even when allowing for a number of variables known to be strongly prognostic in PAH 
including mRAP and cardiac index. This was not the case for WHO FC and it is interesting to note that 
Boucly et al also observed that baseline WHO FC was not an independent predictor of outcome in 
their paper from the French Registry (14).   
In incident patients, an exploratory risk stratification approach separating emPHasis-10 scores into 
three bands based on an equal range of scores in each group (thresholds of ≤16, 17-33 and ≥34) 
identified distinct risk groups with significant survival differences (corresponding one-year mortality 
of 5%, 10% and 23%, respectively). These levels of one-year mortality are very similar to risk 
thresholds of low (<5%), intermediate (5-10%) and high-risk (>10%) proposed by the European 
Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines for risk stratification in 
PAH. Using these risk thresholds, we identified that patients who either improved to intermediate or 
low-risk, or deteriorated to high-risk at follow-up emPHasis-10 assessment had a similar longer-term 
survival to patients who were originally in those risk groups. This effect has been seen in a number 
of other risk stratification parameters and scores (25-27), and the importance of achieving specific 
PROM thresholds in PAH has also been observed with the generic SF-36 (28). The majority of 
patients are in WHO FC III at the time of diagnosis and we were therefore interested whether the 
emPHasis-10 score could refine these patients into higher and lower risk groups. We observed that a 
threshold score ≥34 was indeed able to identify functional class III patients at higher and lower risk 
of one-year mortality at both diagnosis and at first follow-up.  
We observed moderate correlations between emPHasis-10 and exercise capacity (r=0.55 and 0.50) 
and WHO FC (0.50) and only weak correlations with pulmonary haemodynamics (r ranging between 
0.17 and 0.21). The correlations with exercise capacity compare favourably with some reports 
regarding the other 2 PH-specific PROMs; Gomberg-Maitland et al reported weaker correlations 
between 6MWD and the 3 domains of CAMPHOR (symptoms r=0.35, functioning 0.45, HRQoL 0.33) 
in 147 PAH patients while Chin et al observed weak to moderate correlations between domains of 
the PAH-SYMPACT and 6MWD (r =-0.14 to -0.57) in 278 PAH patients (24). More recently, however, 
Reis et al observed stronger correlations between 6MWD and the 3 CAMPHOR domains (r=-0.67, -
0.74 and -0.61) in 49 patients with PAH or chronic thromboembolic PH (22, 29). To date, there have 
been no previous reports of correlations of PH-specific PROMs and pulmonary haemodynamics. The 
correlations we observed were, however, comparable to those observed by Mathai et al between 
components of the SF-36 generic HRQoL tool and haemodynamics in 87 patients with PAH (although 
in their study, many of these correlations were non-significant) (18). 
Finally, we have demonstrated that an improvement in emPHasis-10 score of at least the MDC (≥9) 
at follow-up was associated with an increase in exercise capacity in incident patients whereas a 
reduction in emPHasis-10 score by ≥9 was associated with a decrease in exercise capacity when 
assessed by the ISWD. The vast majority of incident patients will have been started on PAH 
therapies, whereas in prevalent patients there may have been no treatment change between 
assessments, which may partly explain the stronger relationship between change in walk distance 
and change in emPHasis-10 score in the incident group. The reason for the stronger relationship 
between change in ISWD (as opposed to 6MWD) and change in emPHasis-10 is not clear but may 
reflect the different nature of the tests; the ISWT is an externally-paced measure of maximal 
exercise capacity while the 6MWT is an internally-paced assessment of sub-maximal exercise 
capacity. These data suggest that emPHasis-10 is responsive to change, however further work is 
needed to define the minimal clinically important difference.  
 
Limitations 
While this study was able to demonstrate important associations between emPHasis-10 score and 
time to death or transplantation, other measures of clinical deterioration including hospitalisation 
due to heart failure and escalation of therapy were unavailable. In addition, while emPHasis-10 
scores were prospectively collected, this was a retrospective study and there were some data 
availability issues. Treatment data were not available; it is possible that PAH-specific therapies may 
affect HRQoL both negatively, in terms of side effects and the effects of complex treatments on 
lifestyle, but also positively, in terms of improvements in right ventricular function translating into 
amelioration of symptoms. Finally, data regarding comorbidities, such as the presence and extent of 
parenchymal lung disease in patients with CTD-PAH, were unavailable. Assuming that comorbidities 
such as lung disease adversely affect HRQoL the inclusion of patients with parenchymal lung disease 
would likely weaken the relationships between emPHasis-10 and functional parameters, treatment 
response and survival. 
Conclusion 
The emPHasis-10 score correlates with WHO FC, exercise capacity and haemodynamics and is an 
independent prognostic marker in patients with IPAH and CTD-PAH. It has utility in risk stratification 
in addition to currently used parameters. The survival of patients within WHO FC III can be further 
stratified using emPHasis-10 score. Improvement in emPHasis-10 is associated with improvement in 
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Table 1: Patient characteristics 
 All (n = 1745) I/D/HPAH (n = 994) CTD-PAH (n = 751) p value n 
Female (%) 73 66 82 <0.0001 1745 
Age at diagnosis (yrs) 59 ±17 55 ±18 64 ±13 <0.0001 1745 
% incident 35 29 44 <0.0001 618 
FEV1 (%pred) 82 ±21 84 ±19 80 ±23 0.0001 1457 
FVC (%pred) 92 ±23 95 ±20 89 ±27 <0.0001 1459 
FEV1/FVC 73 ±13 74 ±13 73 ±14 0.078 1459 
mRAP (mmHg) 9 ±6 10 ±6 8 ±5 <0.0001 1503 
mPAP (mmHg) 48 ±13 53 ±13 41 ±11 <0.0001 1573 
PAWP (mmHg) 9 ±4 9 ±4 9 ±3 0.56 1496 
PVR (WU) 10.5 ±5.8 12.0 ±5.7 8.7 ±5.4 <0.0001 1378 
Cardiac Output (l/min) 4.2 ±1.5 4.0 ±1.5 4.3 ±1.5 <0.0005 1465 
Cardiac Index (l/min/m
2
) 2.4 ±0.8 2.2 ±0.8 2.5 ±0.8 <0.0001 1305 
emPHasis-10 29 (18, 38) 28 (17, 37) 30 (19, 38) 0.001 1745 
WHO FC I/II/III/IV (%)* 3/23/61/13 4/26/57/13 1/20/67/12  1725 
6MWD* 310 (180, 408) 340 (192, 432) 241 (141, 360) <0.0001 659 
ISWD* 150 (70, 270) 160 (80, 350) 140 (60, 228) 0.001 797 
 
*Variables were recorded at time of baseline emPHasis-10; other variables were recorded at 
diagnosis. Baseline 6MWD and ISWD were available in 38% and 46% of patients, respectively, with 
no overlap.  
Abbreviations: I/D/HPAH = idiopathic/drug/heritable pulmonary arterial hypertension, CTD-PAH = 
connective tissue disease related pulmonary arterial hypertension, mRAP = mean right atrial 
pressure; mPAP = mean pulmonary arterial pressure; PAWP = pulmonary arterial wedge pressure; 
PVR = pulmonary vascular resistance; WHO FC = World Health Organisation functional class; 6MWD 
= six-minute walking test distance; ISWD = incremental shuttle walking test distance 
  
Table 2. Correlation of emPHasis-10 and WHO functional class with walk distance and pulmonary 
haemodynamics 
 6MWD (m) ISWD (m) mRAP (mmHg) CI (L/min/m
2
) PVR (WU) 
emPHasis-10 -0.55* (n=659) -0.50* (n=797) 0.21* (n=575) -0.21* (n=525) 0.17* (n=550) 
WHO FC -0.60* (n=653) -0.59* (n=796) 0.18* (n=572) -0.18* (n=523) 0.18* (n=548) 
 
Correlations assessed by Pearson or Spearman-Rank tests as appropriate. * = p<0.001. 
Abbreviations: 6MWD = 6-minute walking distance, ISWD = incremental shuttle walking distance, 
mRAP = mean right atrial pressure, CI = cardiac index, PVR = pulmonary vascular resistance, WHO FC 




Table 3. Univariate and multivariate analysis in incident patients 
 
 Univariate  Multivariate  
Model 1 Scaled HR p value Scaled HR p value 
Age 2.063 <0.0001 2.177 <0.0001 
Gender (ref. Female) 1.316 0.054   
CTD-PAH (ref. IPAH) 1.336 0.031 1.444 0.017 
WHO FC III (ref I&II) 1.817 0.009   
WHO FC IV (ref I&II) 3.642 <0.0001 2.978 <0.0001 
mRAP 1.196 0.006 1.227 0.005 
Cardiac Index 0.756 0.001   
   
Model 2 Scaled HR p value Scaled HR p value 
Age 2.063 <0.0001 2.180 <0.0001 
Gender (ref. Female) 1.316 0.054   
CTD-PAH (ref. IPAH) 1.336 0.031   
WHO FC III (ref I&II) 1.817 0.009   
WHO FC IV (ref I&II) 3.642 <0.0001   
mRAP 1.196 0.006   
Cardiac Index 0.756 0.001   
emPHasis-10 1.518 <0.0001 1.447 <0.0001 
   
Model 3 Scaled HR p value Scaled HR p value 
Age 2.063 <0.0001 1.860 <0.0001 
Gender (ref. Female) 1.316 0.054   
CTD-PAH (ref. IPAH) 1.336 0.031   
WHO FC III (ref I&II) 1.817 0.009   
WHO FC IV (ref I&II) 3.642 <0.0001   
mRAP 1.196 0.006   
Cardiac Index 0.756 0.001   
emPHasis-10 1.518 <0.0001 1.226 0.047 
Walking distance* 0.461 <0.0001 0.574 <0.0001 
 
*Two types of walking test were used (the 6-minute walking test and incremental shuttle walking 
test). For Cox regression modelling, distances were converted to a z-score and combined.  
Abbreviations: IPAH = idiopathic pulmonary arterial hypertension, CTD-PAH = connective tissue 
disease related pulmonary arterial hypertension, WHO FC = World Health Organisation functional 
class; mRAP = mean right atrial pressure, HR = Hazard Ratio 
  
Figure 1: Distribution of emPHasis-10 score by WHO functional class at baseline Abbreviations: WHO = 
World Health Organisation 
 
Figure 2: Kaplan Meier survival curves demonstrating survival from baseline emPHasis-10 score for a) 
incident patients; b) prevalent patients; c) all patients; d) risk transition in all patients between baseline 
and follow-up emPHasis-10 score Abbreviations: NS = not significant 
 
Figure 3: Survival in incident patients with WHO functional class III symptoms, dichotomised by 
emPHasis-10 score ≤33 or ≥34. Abbreviations: WHO = World Health Organisation, E-10 = emPHasis-10 
score  
 
Figure 4: Change in walk distance (ISWD or 6MWD) in patients whose emPHasis-10 score deteriorated 
by ≥9 or improved by ≥9 between baseline and follow-up. Figure 4a & b: all patients, figure 4c & d: 
incident patients, figure 4e & f: prevalent patients. Abbreviations: ISWD = incremental shuttle walking 
test distance; 6MWD = six-minute walking test distance; E-10 = emPHasis-10. Violin plots: dashed line 
= median, dotted line = 25th and 75th centile 
  
 
  
 
  
 
  
 
